Q2 2025 Stryker Corp Earnings Call
Welcome to the second quarter 2025 Stryker earnings call. My name is Megan and I'll be your operator for today's call.
At this time, all participants are in a listen-only mode.
Following the conference, we will conduct a question-and-answer session. This conference call is being recorded for replay purposes.
Before we begin, I would like to remind you that the discussions during this conference call will include forward-looking statements.
Factors that could cause actual results to differ materially are discussed in the company's most recent filings with the SEC.
Also, the discussions will include certain non-GAAP financial measures.
Reconciliations to the most directly comparable, gaap Financial measures can be found in today's press release, that is an exhibit to Striker's current report on Form 8K filed today with the SEC.
I will now turn the call over to Mr. Kevin Lobo chair and chief executive officer. You may proceed sir.
For today's call, I will provide opening comments, followed by Jason with the trends we saw during the quarter and some product updates.
Press in will then provide additional details regarding our quarterly results and guidance. Before opening the call to Q&A,
Our second quarter results, reflect being in diverse and attractive and markets, our focus on Innovation and disciplined operational execution.
We delivered double-digit organic sales growth of 10.2% and adjusted EPS growth of 11.4%, while managing through the impacts of tariffs, Inari, dilution, and the spinal implant divestiture.
Our robust organic sales. Growth was driven by strong demand across our product portfolio.
And included double-digit growth from MedSurg, neurotechnology, and high single-digit growth for Orthopedics.
Geographically, our U.S. organic sales growth of 11.5% included double-digit organic growth from our Endoscopy, Neurocranial, Trauma, Extremities, and Instruments businesses, and high single-digit organic growth in Medical and Hips.
We delivered 6.5% organic international sales growth, despite supply chain challenges, with notable contributions from South Korea and emerging markets.
We continue to see international markets as a big opportunity for future growth.
As a growth company, we are excited to continue delivering innovation both internally and through M&A.
We maintain a healthy deal Pipeline and are well prepared to capitalize on a broad range of opportunities.
We exited Q2 with strong momentum and are well positioned for the second half of the year.
As a result, we are raising our full-year 2025 outlook, which includes delivering another 100 basis points of adjusted operating margin expansion.
We are confident in the durability of our growth and earnings power across our businesses.
With that, I will now turn the call over to Jason.
Thanks. Kevin, my comments today will focus on providing an update on the current environment, capital demand, and the integration of Inari Medical.
Procedural volumes remain healthy in the second quarter, driven by the continued adoption of robotic-assisted surgery, a stable pricing environment, favorable demographic trends, and the ongoing shift toward ASCs.
We anticipate continued strength and procedural volumes as we move into the second half of the year.
Demand for our capital products was strong once again in the quarter, and we exited Q2 with an elevated backlog.
With healthy hospital capex budgets, we expect continued strength in our order book for the remainder of the year.
We are also excited to share that during the quarter. We reached a milestone of 2 million robotic procedures performed with makeup.
We are the clear leader in Orthopedic Robotics and continued to launch new applications. Such as revision hip which is receiving very positive. Surgeon feedback.
Also we delivered our best ever Q2 for Maaco installations both in the US and worldwide with high utilization rates across the globe.
Momentum from installations and utilization to continue to drive growth in our hips and knees businesses.
The launches of Mako spine and shoulder are going well, and remain on track for full launches as discussed on our last earnings call.
Our platform launches, such as Life Pack 35 and the Pangaea Plating System, continue to have success in the marketplace and are driving meaningful contributions to growth.
We recently received approval for Life Pack 35 in Europe and are on track to launch in late Q3.
As a reminder, many of our new products are still pending approval in Europe, such as Insignia and Pangea.
In addition to these launches over the past several quarters, we have introduced a number of next-generation and innovative products across our diverse businesses that continue to drive our growth.
Lastly, we continue to make solid progress on the integration of Inari.
We did experience some disruption in Q2 including working through destocking over the first half of the year, as well as the onboarding of new sales professionals.
We have moved quickly to convert the business to our Striker offense, which will position us well for the future.
Even as we navigate these changes, we still expect double-digit pro forma revenue growth for 2025.
With that, I will now turn the call over to Preston.
Thanks Jason today, I will focus my comments on our second quarter Financial results and related drivers.
Our detailed financial results have been provided in today's press release.
Organic sales growth was 10.2% for the quarter compared to 9% in the second quarter of 2024.
This quarter had the same number of selling days as 2024.
Pricing had a 0.5%. Favorable impact with both our Med Surge and neuro, technology and Orthopedic segments continuing to see overall positive Trends from our pricing initiatives.
Additionally, foreign currency had a 0.8% favorable impact on sales.
Our adjusted earnings per share of $3.13 was up 11.4% from the same quarter last year, driven by our robust sales, growth, and margin expansion, partially offset by higher interest expense.
Foreign currency translation had a favorable impact of $0.04.
Now, I will provide some highlights around our quarterly segment performance.
In the quarter, MedSurg in Neuro Technology had organic sales growth of 11%, which included 12.5% of U.S. organic growth and 5.7% of international organic growth.
Instruments had us organic sales growth of 10.1% led by double-digit performance from our surgical Technologies business which includes our Neptune waste management and smoke evacuation products.
The number of states that have passed smoke-free legislation continues to rise with 19 states to date, having approved most free operating rooms these states. Represent over half the national population.
Endoscopy had us organic sales growth of 18.6% with strong double digit performances across all businesses growth was fueled by robust demand for operating room, infrastructure and Renovations. And the continued success of the 1788 video platform, as well as our sports medicine business, which has expanded its portfolio through the launch of several new shoulder products.
Medical had us organic sales growth of 9.9% led by double digit performance in the acute care business. Somewhat offset by lower sales in the emergency care business, through the continuing Supply disruptions that are now expected to linger through the end of the year.
From a product perspective, the supply matters do not affect life pack, 35.
Vascular had us organic sales growth of 1.4%.
We expect improved growth in the second half of this year, led by recent launches of our Surpass Elite Flow diverting stent, Access Lift, Inc. cranial base catheter, and Broadway large bore aspiration catheter. As a reminder, organic sales figures do not include Inari.
And finally neurocranial had us organic sales growth of 14.8% led by strong double-digit growth in our Neurosurgical and IVs businesses and near double-digit growth in our cranial, Maxell facial business.
Internationally, MedSurg and Neuro Technologies saw organic sales growth of 5.7%. Despite the supply disruptions in medical mentioned earlier.
Growth was led by our neurocranial instruments, endoscopy and Vascular businesses.
Geographically, this included strong performances in South Korea, Canada, and our emerging markets.
which included organic growth of 9.7% in the U.S. and 7.5% internationally.
Our U.S. knee business grew 6.2% organically, reflecting our market-leading position in robotic-assisted knee procedures and continued momentum from new MCO installations.
Our U.S. hips business group grew 8.4% organically, reflecting the ongoing success of our Insignia hip stem and the continued adoption of our Mako robotic kits platform.
Are you using these business grew, 13.6% organically with double-digit sales growth in our core trauma and upper extremities businesses. Our core trauma performance, continues to be driven by Pangea. Our differentiated plating portfolio which also hit its 1 year anniversary of launch in the quarter and continues to generate robust interest and adoption by the market.
Our us other Ortho business grew, 5.6%, organically, led by strength of Mo installations and a strong performance in navigational. Technology, products offset by bone cement.
Internationally Orthopedics, organic growth of 7.5% included, strong performances in South Korea, Japan, and many of our Emerging Markets. Additionally, our International results. Do include a nominal amount of spinal implant Revenue because of previously, accepted tenders that we are fulfilling before exiting those markets.
Now, I will focus on certain operating and non-operating highlights in the first quarter.
Our adjusted gross margin of 65.4% was favorable by 120 basis points over the second quarter of 2024, despite the impact of tariffs.
The Improvement was primarily driven by cost improvements and businesses.
Our adjusted operating margin was 25.7% of sales which was 110 basis points. Favorable to the second quarter of 2024 driven by the gross margin favorability. I just discussed
adjusted operating expenses as a percentage of sales were consistent with prior years.
Adjusted other income and expense of $106 million for the quarter was $52 million higher than 2024 due to the increased interest expense from our September 2024 and January 2025 debt issuances, slightly offset by favorable foreign exchange impacts.
For 2025, we continue to expect our full year adjusted other income and expense to be approximately 430 million.
The second quarter had an adjusted effective tax rate of 15.9% reflecting the impact of geographic mix and certain discreet tax items.
For 2025, we continue to expect our full-year effective tax rate to be in the range of 15% to 16%.
Turning to cash flow, our year-to-date cash from operations was $1.4 billion, driven by higher net earnings and year-over-year working capital improvements.
And now, I will discuss our full year 2025 guidance.
Considering our year-to-date results, strong demand for our products, and our operational momentum, we're raising our full year guidance. We now expect organic net sales growth of 9.5% to 10% and adjusted earnings per share to be in the range of $13.40 to $13.60.
Our updated sales guidance includes a modestly, favorable pricing and path. In addition, foreign exchange is expected to have a slightly positive impact on both sales and earnings per share should rates hold near current levels.
We now estimate a net impact from tariffs of approximately $175 million in 2025.
This estimate, which is consistent with the amounts, we have previously, discussed does reflect the reduction in the bilateral, us-china, tariff rates, and the announcement of a new framework agreement with the European Union.
We continue to take thoughtful measures to address this estimated impact, which we are offsetting through our continued sales momentum, the leveraging of our manufacturing footprint, disciplined cost management, and better-than-expected foreign currency impacts. And with that, I will now open up the call for Q&A.
Open the floor for questions.
If you would like to ask,
Phone keypad. You may remove yourself at any time by pressing Star 5 again.
We would like to remind callers to please limit themselves to 1 question and 1 follow-up question, so we can accommodate as many participants as possible. We will pause just a moment.
Our first question will come from Larry Biegelsen with Wells Fargo. Your line is open.
Uh, good afternoon. Thanks for taking the question. Congrats on, on a nice quarter here.
Buy issue, impact growth this quarter. And and when exactly do you expect to resolve the issue and I had 1 follow up, please.
Yes, thanks. Uh, Larry, I would say what Jason mentioned related to procedural strength, and we've even seen that in the month of July. You know, continued procedural strength, and that includes implants as well as other procedures across the surgical space. Strong capital demand; our order book is very healthy. We're not seeing any slowdown at all on capital. The supply issues are really limited to medical; the rest of our supply chain is in really good shape. And those issues will continue to persist throughout the year. But medical has a lot of other products that they're continuing to sell very well, including Pin Pangea, sorry, including Light Pack 35. And we're very excited that Light Pack has now received European approval, so that we'll start to see it in Q4. So, overall strength across our portfolio, strong demand for the procedures, strong capital demand, and that's why we decided to raise it to the level we are. We're very confident in the topline outlook.
That's very helpful, and Kevin remanufactured instruments are a hot topic. Again, you have unique insight into this with the sustainability business. How are you thinking about remanufactured instruments for soft tissue robotics? Do you see that as a good opportunity for Stryker? And if so, how would you enter the market? Thanks for taking the question.
Yeah. Thanks. You know, Larry, you don't really talk about our pipeline, and this would be a pipeline product. And so, there is another company that's obviously getting into the business. If we decide to enter that, we'll let you know when we do.
All right. Thank you very much.
Our next question will come from Robbie Marcus with JP Morgan? Your line is open.
Oh great. Uh, congrats on a nice quarter. Uh, thanks for taking the questions. Uh,
Maybe first, uh, Preston, it's impressive. Uh,
Margins here. Um, in the quarter, the EPS guide is now basically um,
Back to where it was almost, uh, pretty tariff, pre-andere dilution.
Um, maybe just walk us through what? What's driving?
The uh, the strength and the underlying margins here to get you almost back to the original guidance. Um, especially as, as you're, you know, absorbing all of these diluted pressures.
Yeah, thanks for the. Thanks for the question Robbie. So a few things I guess first I'd point to you know, we started as we came through the pandemic, several years ago, we really focus on price and so that, that focus on price has continued. And so we're seeing the benefits of that slowing down and really helping us to drive margin. In addition, we've talked about this continued focus on our, our manufacturing uh, efficiency and really getting our operations in into a more efficient.
Uh, manner in terms of supporting the sales growth that we have. And so we're really starting to see that take shape as well and we have a lot of different initiatives going on from from different lean initiatives in our manufacturing facilities to uh different initiatives happening across our procurement organization, as we think about how we Source product where we Source product. And so all of those are certainly helped us helping us to drive the the additional margin improvements that you're seeing. I think we're also just getting more efficient with with where we have product and how we're moving product through our supply chain, which is leading to some some reduced costs as well. And then finally, I would just point to we continue to look at how we support the business from an Opex, standpoint really thinking about GNA, as we look at shared service centers and and other areas like that, as we continue to support the business. The good news is Robbie is and I'm I'm I'm really pleased with in the first quarter. We saw a consistent, a consistent delivery of that op margin. So 100 basis points in the first quarter or 100 basis points in the second quarter which is really helping us to be much more consistent as we drive to the number that Kevin was talking.
About our overall 100 basis points of delivery for the year. So all these elements that we've been putting in place, over the last few years are really starting to take shape and allowing us to to drive a more consistent margin story.
Great. Uh, maybe a a follow-up. Kevin. Um,
In the the outpatient rule, we saw proposal to move. Um,
A heart ablation into the ASC. For the first time. I know you 1 of your favorite things is whenever you see a construction cranes up you, you love it. Um, I was wondering if I could just get your thoughts on where we are in the ASC build out. I know, most people with respect to Stryker focused on Orthopedics, but how you're thinking about asc's um, across other, uh, parts of the hospital and Striker's part in it?
Saw it with hips and knees and it'll continue. Whether it's Cardiology even general surgery. I could see, uh, a lot of those type of more elective procedures being done in asc's. This trend is not going to stop because it actually lowers the cost of healthcare. It's a pleasurable experience for the surgeons. It's a pleasurable experience for the patients and I could see that healthy patients like to go to a place like this where there aren't sick people.
And so, I absolutely see this trend continuing, um, if you look at something even like total, ankle, right, we just had nice reimbursement increases. Uh, both in the hospital, outpatient as well as in the asc's for total ankle. So if you ask me 5 years ago, would we be doing total ankles in the AC? As I wasn't even sure about that. And now that the the reimbursement was raised 7,000 because fusions aren't nearly as successful as total ankle. So this trend is absolutely going to continue. Uh, there's no doubt about it and I think you'll see it across all specialties
Appreciate it. Thanks.
and, and we like construction, as you say because we do have a lot of products, even in those Specialties we don't plan, we do provide a lot of infrastructure that's used uh and even even another specialist
Our next question will come from Ryan.
Zimmerman with btig, your line is open.
Uh, thank you. Thanks for taking our questions. Um,
Preston, last quarter, I think you called out the tariff impact at about $200 million. If I heard you correctly, it's $175 million. Now, most companies we've seen have come down, maybe by about half. I'm just wondering if you could elaborate on why it's only coming down by about $25 million. Is that a reflection of some of the manufacturing locations and so forth?
Um, and on that, thanks for the question. We were right. Last quarter, we did call out 200 million, we've come down to about 175. A few things, I would probably point to in our original estimate if you may recall, we we were just quoting. What was in place at the time. So at that point in time we really had the Baseline. 10% that was included for most areas other than some of the uh specific industry elements around steel and aluminum and then I think Canada and China had or Canada and China and Mexico had some different ones at that point in time. As we as we fast forward here into the second quarter, the big change that we're seeing or the 2, big changes that we're seeing the bilateral agreement with China. And the US has brought that that tariff down pretty significantly. And so we saw some benefit in our number as a result of that. But then we did see some offsetting increase as Europe as as entered into the framework of of going to 15%, which would have been in our model 10% previously. So we're seeing some puts and takes, which is what gets us to that number and you're right. It is reflective of how our man.
Manufacturing footprint is is set up.
Yeah, it's our manufacturing footprint in Europe as well as us not being as strong in China as other companies. So, that's that's why it affects us. Maybe to a little bit of a lesser degree than others.
That's fair enough. And then, you know, the second question is just, um, we've seen some kind of install base numbers out there on Orthopedic robotics, uh, you know, out in the market. Uh, you know, Kevin, I'd love to hear your thoughts on kind of what you see, as Greenfield opportunities, uh, within makeup at this point and obviously an install base number is always appreciated. But um, you know, how you think about that versus kind of maybe adding, you know, the second and third robots at at various sites around, uh, the world.
Thank you. Well listen, I can tell you in the United States. There's very few places that only have 1 makeup
If they have 1 makeover, they tend to have more than 1, and that those Universe of opportunity for us as every single operating room that does Gibson needs. That's our universe. So, there are 5,000 hospitals that that do procedures and.
They have a lot of operating rooms, so there's still a huge room for us to continue to grow with robotic installations installed Base number. We may provide at the end of the year, when we, uh, when we provide our sort of percent of procedures being done, which continues to climb. So I'll talk to Jason and Preston. We may provide that number at the end of the year and we we tend not to like to be the only person providing these numbers, but but we'll, we'll take, we'll take that under consideration and I would tell you internationally,
We're really starting to pick up steam and we're kind of where we were in the US about 5 years ago, especially places like Japan, um, and parts of Europe and Latin America. So, uh, we still have a long Runway to go where I would say, we're still in the early Innings overall in the robotic penetration.
Thank you.
Our next question will come from Joanne Wish with City Bank. Your line is open.
In, um, in the spring at AOS, which had the shoulder of the hip and the knee and the spine applications all together. Um, how is that going? And um, anything you'd say on shoulder and spine would be great. Thank you Joanne. I'll take, I'll take the first part of this Joanne, as it relates to the supply issues, and then Kevin can jump in here on on Mo, but as it relates to the supply issue. Um, you know, and I think Preston touched on this as well. Largely in the medical division. We do expect it'll kind of linger, uh, throughout the remainder of the year. That being said, I I think what you'll see of of Medical in the back, half of the Year growth will accelerate and, um, you know, double digits in terms of organic sales growth for them. Well, within reach as we think about the full year,
Yeah, great as it relates to make a 4. Uh so we're really excited about this launch and now this is not yet a global launch. So that we do have countries around the world where we're still selling Mo 3 and what we added with make a 4. So the hip revision application is only available on ML 4. There's fine application is only available on ML 4 right now. The shoulder we were in a limited launch on shoulder because that's actually on the Mako 3 and we're in the process of of migrating, the shoulder to make a 4. So that'll be available starting at the beginning of next year, on on, Mako 4. And that's why part of the reason why the shoulder launch won't be a full launch until next year because we do want to launch that with, with Mako 4. But so far, so good, the feedback has been very good. We haven't moved to a full launch on spine yet. Uh, for the same reasons of just
Getting the workflow, right? And getting good feedback. And also we have to partner with the, with VB, spine to be able to do these deals, which include the robot, as well as, uh, the implants. And, and we're working through those commercial, um, contracts and and methodologies, but, but everything so far is looking really good. We have very good applications, very well received by customers. Not going to have much of an impact on our sales. This year start to see much more of an impact next year.
Our next question will come from Travis deed with Bank of America. Your line is open.
Hey, thanks for taking the question. I wondered off the question on on nari. I don't know if you could maybe help with how the business grew this quarter with the dto and sales rep Transitions, and what gives confidence and double digit growth in 2025. Um, and then can you get back to kind of market growth rate, uh, in 2026.
Yeah, listen. Now you know these stocking is not fun. We've been through this before, by the way, when we bought other companies k2m, we went through that. And a lot of these uh these kind of earlier startups, have these kind of practices 1 of their practices was quarterly incentives which which helped to drive the stocking. We've done away with that practice. We've also replaced the sales leader with a Stryker sales leader. We've replaced the marketing leader with a marketing leader from striker. Of course, the president came from Striker as well and had prior experience, um, in the peripheral vascular space. So we have a striker leadership team that's really in place, which is exciting. We also took some medicine
On forcing all the sales reps to sign non-competes outside of California and, uh, that was a bit of a gutsy move when you're you're buying a deal for sales and then you're making sales people signed non-compete. Some people deflected, not to do that and we took our medicine and we've been rapidly hiring uh, new salespeople. The good news is the underlying actual procedural demand was double digits. So we it's not like we are procedures and the surgeons doing our products were were below market. So we're in pretty good shape. Um, from a procedural standpoint In Stocking we'll burn out. So we're not too worried. In fact, the second half of the year will be good. And the overall year we we expect to be in double digit growth when. So, the most of the, the Bad Medicine has been taken already. There's still a little bit more stocking, probably to burn, but overall we're setting this up for the future and we've learned through the in the past is take your medicine early on these kind of deals. And uh, we love the pipeline. I was just actually had an ring earlier this week. My second visit down there and pipeline is great, talent is really good, uh, but
We've moved them now to a Stryker sales offense and put striker people in charge. And this is what we're really good at. I mean, they have they are they developed this Market, they have amazing clinical trials that are underway as well. Uh, International is still tiny for them and has a huge opportunity, leveraging, our infrastructure. So very, very pleased with an arai being part of the strike report portfolio and, um, and they're a good times ahead even as early as the second half of this year and certainly into 26 to 27.
Quarter.
Yeah, it sounds like a couple of couple of questions there, Travis, but I'll take it. This is Jason. So, first off, uh, on the bill side of this, uh, as you can imagine we are, we are continuing to monitor the situation, you know, as you think about procedures for us that involve Medicaid. It's really an immaterial, uh, amount of procedures for us. So really, uh, knowing what we know today, no concerns there for us, uh, as we think about the bill, but again, we'll continue to, to monitor that on the knee. Front, I'll say a couple different things. So, um, you know, as you think about how we exited Q2, June can be with vacations and some of those things, a little bit of a slower month. We saw a little bit of that. I'll tell you, as we went into July off to a really nice, uh, start for the quarter. Um, so overall I would say, uh, no concerns about the knee Market. Uh, we continue to think this will be a kind of a mid single digit Market with us growing above Market obviously. Um, and then just the last thing I would say it's 1 quarter.
Right? So, you see some of these fluctuations as you go throughout the year, but, uh, but overall feel really good about the year.
Great. Thanks. Jason.
Our next question will come from David Roman with Goldman Sachs your line is open.
Hi, this is Jenny Rabinowitz on for David. Um, You probably have the international expansion opportunity for a few quarters and you have a Pangaea and Insignia launching in Europe. I was hoping you could break down how you're thinking about inorganic versus organic investment especially as it relates to um, International and expansion in new countries. Um, thinking also here, any Reflections on the surface, you kind of anniversary that goes at acquisition and expansion for Orthopedics in Europe.
Thank you. Yeah, thanks for the question. So, surf has gone extremely well. We're really, really pleased. You can see our hip business has been has done very well internationally and, and yes, it'll it'll last and it's now be it's going to become part of organic and uh, we, in fact, we're actually going to be bringing our first surf product to the United States shortly. So very pleased with that. Uh, acquisition and integration. We haven't done a lot of deals like that that are primarily Revenue based outside the United States. We continue to look for those types of opportunities. I would tell you that the biggest opportunity frankly is is increasing the penetration of products. We already have in our portfolio internationally and especially Acquisitions that primarily have us Revenue taking those Acquisitions to the internal International markets such as Inari. So obviously this quarter International is a little bit slower than it's been over the past 3 or 4 years but nothing alarming there. Uh, Pangea just to be clear is not yet approved. Um, so that probably won't be approved until next year and
Insignia is still not approved. The only 1 that just got approved was a life pack 35. So unfortunately, this EU MDR has been a, a real challenge, not just for Striker, but for the whole industry of much slower regulatory pathway for products. And so, a lot of the super cycle launches that we that were enjoying in the United States are still not arrived in in many other International markets in some cases, we're launching in Japan before Europe.
Which was unheard of 3 or 4 or 5 years ago prior to UMD. So I think this slide slow down here. It's still good growth rate. You know, in your when you're above 6% growth, that's still pretty good but uh, not that we're accustomed to. We do expect to get back in the second half of this year. International growth will be much better than it was in the second quarter.
Our next question will come from p.
Chickening with Deutsche Bank, your line is open.
Hey uh good afternoon guys. Uh, so 2 questions here, the first 1 is on the guidance raised, you know, really nice raise here. Uh, but could you bridge us, the, the EPS increase you saw as it relates to uh, better pricing than expected, uh, FX. I changed it to terrorists versus your core operational strength.
Yeah, so Peter, thanks for the question. We can walk through a little bit as we think about the the the guide is really reflective, as Kevin mentioned, before on our strong performance and our expectation really on the top line of where we expect to continue for the rest of the year. The, the bottom guy, the bottom part of that, and the EPS side of that is really just the flow through.
Of that, that upside that we see, as you remember when we talked about tariffs, part of the way that we're covering off on tariffs is through some spend discipline and some other areas. And so, that's not necessarily going to 100% flow through to the bottom line. As we're still trying to spend behind our growth initiatives, the other elements really, we do see some favorable FX that does flow through a little bit as well. So really, what you're just seeing is that top-down flow through from the strong performance that we've had. That's the other thing I would just point to; we do have a little bit of a wider range on the bottom, and a lot of that just reflects some of the continued uncertainties primarily due to macroeconomic elements, like tariffs that we know are still going to have some pluses and minuses for the rest of the year.
I'm still not understand the 19 plus percent growth. You saw in Endo in the US uh this quarter up quite a bit, you know, versus first quarter comes through easier but still a pretty big move up. Are there any reclassifications? Uh skewing that number or not just walk us through kind of you know that that that great growth. Thank you. Yeah, first thing I say no reclassifications know accounting um issues whatsoever. Just pure uh fantastic performance from the endoscopy Division and you know look at last year was it was
It was an 8% cost, so it wasn't exactly soft. But, yes, it was a little bit lower than, than the typical double digit. But it was a boomer of a quarter for our endoscopy Division and it was really across the portfolio. So the booms and lights in in our Communications business had a phenomenal quarter. And uh, and they have great orders. They have the new ocul on light that they've launched which is has tremendous demand. So Communications will continue to whom the rest of this year. Um, and then, of course, the 1788, and the end. What we call the endoscopy business unit at a, at a terrific quarter, and that's just been a consistent Trend that we've had. And then sports medicine is just on fire, and you're talking about very strong double digit growth. They launched about 6, uh, shoulder products over the past. Let's call it 6, to 8 months and those products that shoulder was the 1 area. We were not quite as strong as, as hip and knee in sports medicine, and they had a absolute Boomer. So she had sort of all the business units kind of clicking. At the same time we also have our reprocessing business. That's part of
Um, the endoscopy, they also had a solid quarter as well. So really 1 of those quarters where kind of everything caught fire. Uh but but this is a division that's been performing very consistently, very high growth quarter after quarter after quarter, just a little bit uh higher than normal. Let's say this quarter which uh, which of course we enjoy,
Great. Thanks so much.
Our next question will come from Matthew O'Brien with Piper, Sandler. Your line is open.
Good afternoon. Thanks for taking my question. Um would love to talk a little bit about Mo again just you know the the commentary about record new system adds is is great to hear again but I mean you've been doing that for a while anything you can call out as far as what's driving that again here. I know it's YouTube but is it, is it, you know, the having the shoulder application, the spine application, more people are interested or is there any kind of pause around, you know, competitive launches, um, just anything to call out there because again, you know, um, you continue to put up these great Mo numbers quarter after quarter,
Yeah, listen, I was really pleased with this quarter and this is a first quarter of a of a new makeover. So make a 4 and I was honestly just not sure that it would a new robot would might cause a little bit of a pause. Hasn't caused any pause whatsoever. Our team is executing the robot is performing extremely well the word is out. You know we have a fantastic robot the revision hip uh the surgeons are buzzing about it. Just make some very hard procedure easy to do. They can see exactly where they're
Putting their screws and and which part of the bone and do you help a surgeon out on something that's very difficult? They enjoy that very much but uh I was actually a little bit pleasantly surprised with the with the performance. Just based on when you're changing a cycle, you know, other companies have gone through, we do this in cameras, we do this, in power tools, we had never done it before. Uh, in Mako, and it has been absolutely seamless in the United States, this transition, and they want their next robot and their next robot. There's been a few sort of coastal customers that are saying. Well, can I, I just bought a 3. Can I upgrade it to a 4? And so we're having some of those discussions. But uh we'll be very friendly to our to our customers and help them upgrade if they want to upgrade to the the new robot, a lot of customers are saying, okay, well I'll just I'll keep the 1 I have and I'm just going to buy another 1 for the next operating room. And um so so we expect this to continue and the funnel like we have a we have a visibility into the future. So we expect this momentum on Mako to continue and there are a lot of operating rooms still that don't have robots. So those are all Targets.
That I appreciate that. And then as the follow-up, you know, Kevin your your your pretty um you know um transparent as far as just the thoughts on on you know your m&a strategy and you know talking about a full pipeline should we expect another sizable type transaction? Maybe not quite as big as the nari um you know uh for you guys and you know the near future is somewhat near future and and you know you've also given us some kind of some of the the areas that you're interested in anything else that you would kind of highlight, it might be new to that list or or something else that that you're really um, a little more focused.
Focused. I don't know if it's soft tissue robots, Etc. Thanks so much.
Want to continue. So that'll that there's a pipeline there of of deals that they were looking at themselves that that we're going to start to evaluate. I would say that we have the financial bandwidth to be able to do another Inari, size deal. But I can't really predict, you know, when you know deals are uncertain. You don't know when you're going to do a deal and and what size, the bulk of our deals will continue to be the the tuck in variety. If you think about last year 7 deals, we did.
That's kind of the normal Striker office and then every once in a while we do a bigger deal like a a Right medical or an Inari. So I I really can't give you more on that. We we are always looking at right? We our teams are out there scouring the market. We have a nice Pipeline and we have a number of IIs in process, but those sometimes wash out and based on the price based on our due diligence. And so it's kind of hard to predict, but I'd be pretty surprised if we don't announce anything for the rest of the year, they'll they'll be a deal or 2 or 3. I don't know exactly how many most will be tuck in. Um, and, you know, it's not impossible that we wouldn't do something bigger. We certainly have the band with financially and and, uh, and you know, I like to spend money soon.
We'll be active.
Thank you.
Our next question comes from Vijay, Kumar with evercore, your line is open.
Hi guys, thanks for taking my question and uh, grew up in a nice cabin. Um, maybe to a product, uh, segment kind of questions, uh, first on on manipulating questions around.
For capex environment. So maybe if you could just uh touch upon the broader capex and modern and and LP 35 launch and how that's Pro progressing.
Yeah, VJ, this is Jason. I, I think I got most of your questions there. So I'll take a run at it here, but I, I think the questions on the capitol environment. I would say, you know, in similar to my prepared remarks here, we, we feel really good about the capital environment. Uh, if you look at our Capital backlog, again, it remains very elevated. No, signs of slow, slow down there as we think about the rest of the year. So, so, so really confident in that business, for sure.
Yeah, and the life stock 35.
Yeah. LP 35 is doing really well. Really strong order book again. We're still waiting for certain approvals now just getting the European approval. Is is exciting. So, September, we're going to have this kind of a launch, uh, in Europe of LP, 35, but great customer feedback. Uh, it's doing really, really well. And you know, these medical launches, they're a little different than sort of cameras or power tools like this will have a long it'll be we'll be talking about it as a kind of a new product 3 years from now they they have a longer cycle of of contribution to growth a longer, uh, Tailwind than you
You see with, uh, with even for security right is continuing to had a really great quarter in, in Q2, it was launched a few years ago, but it, you know, that, as these are long-term product Cycles, so they'll continue to be Tailwind for a long time to come.
That's helpful, Kevin and maybe 1 on that Niche here. Um you know comp was this just complicated or um anything else that's going on within within the uh need performance.
Hey, BJ know, I wouldn't say there's anything um else material to call out other than what I've already said again. Feel really good about the knee Market feel good about the full year and and like I said earlier July off to a good start here, so really nothing additional that
Fantastic. Thank you guys.
Our next question.
Comes from Matt, mixed with Barklay. Your line is open.
Great. Thanks so much for taking the question. Um, so I wanted to follow up on um on Interventional spine. Um, just the, you know, the launch of um opto Blade the Investments that you've made in that segment would be great if you could talk a little bit about, you know, any of the the, you know, quantitative or qualitative metrics about the launch so far, the other products and the Investments that you're making uh and and the growth and then I had 1 follow up.
Yeah, listen, we we love our Interventional spine business, obviously that that's reported under neurocranial. And we've been frankly 1 of the fastest growing businesses in Striker, over the past 3, or 4 years has been IVs. Uh, We've added to that with oplate initially the oplate launch, which is an organic launched. And now we have the off the blade, BBN launch, which is just happened. We also have the virto acquisition we did last year, which for now is not appearing in organic sales growth. But will later this year, um, I would say that business is just cooking on gas. We have an amazing leader of the business, a great management team.
Balloon has been terrific. We did the spine, Jack dealings original spine. Now we have Opa blade and so we've we're covering oncology as well as pain and adding salespeople and and just uh just a fantastic business, a little gem, it's not huge yet. But it's growing really really fast but it's 1 of the gems of Striker and it's kind of how we drive this kind of growth. So consistently as you have a number of these smaller business units,
That we continue to to fuel really high growth like, very consistent, strong double digit growth and I don't think that's going to slow down whatsoever. It's going to continue especially with these vertos is off to a really good start and then the bvn is very new but so far getting good feedback.
That's great, that's great. And to follow up with just on, um, not to do a poll of, you know, keyword Bingo here. But but um, but but AI is something that we haven't talked about in a while. I know, you know, Robert, I'm sure wakes up every day, thinking about it and probably goes to sleep working on it. Um, but, you know, maybe talk a little bit about some of the digital efforts that you're, you're, you have underway around whether it's Orthopedics or other segments of the business and and where we might start to see more um of you know Striker putting it.
Substantial data and, and assets and digital Technologies to, to work, uh, to deliver, you know, Solutions in that area. Thanks.
Hey thanks. Uh we have a lot going on in the world of AI. Um you know that blueprint is already a FDA approved and and uses AI to create the surgical plan and and inform the surgeon as to which implant they should be doing.
Pre-planning is going to be continued. We're going to proliferate that across our portfolios as one area of opportunity. We have the device that quantifies hemoglobin and sponges—that's an AI product approved. We have a number of other projects, and in addition to that, we've hired a new Chief Digital Information Officer, Deborah King, who started pretty recently and has a lot of experience, especially in generative AI, and is also going to bring a lot of infrastructure that can then be used by our divisions. I would say that this is a topic that we'll probably cover in our Investor Day.
That's planned for later this year, we'll get the specific data out shortly, but rather than spending enough time on the earnings call, going through this, I think we'll give you a lot more information on that later this year. But suffice to say we are absolutely aggressively working um in this area and see this as a a tremendous opportunity to bring more science to Health Care uh versus just relying on 1 surgeon experience in their residency and in their training to be able to bring more data to life. So we have a lot of projects underway, we'll share more later in the week.
Thanks. Kevin.
Our next question will come from Steve Lickman with Oppenheimer & Company. Your line is open.
Thank you. Uh, evening, guys. Uh, Kevin you talked about uh, Salesforce change out at Inari, as you put non-competes in place, uh, can you talk about, you know, how much sales this is going to do? You're assuming as a result, and I know you mentioned still double digit growth. But as the absolute expected reported expected Revenue contribution from an RA change at all,
Yeah, looks like with full year. I think we talked about something like 590 million for the full year. We're going to be right around that number. So we're absorbing these these changes. Um, these challenges of of sales repetition, it was starting to happen even before the deal, you know, closed. And we accelerated that with the non-competes and look, a lot of those people that decided not to sign on. We're not necessarily all regrettable not necessarily Striker, type of sales people, we've been aggressively hiring. So we know we're not, we're not calling down our number but it's a little bumpier so it was a little lower in the as we decked and as we dealt with the turnover, but the the reps are coming on and we're going to expect very good numbers in in Q3 and Q4. Yes, Steve. Maybe just to add just a finer point on that, on the 5990, just to be crystal clear here, that would be for the 10-month period. Um, since we've owned a
Uh, we'll see that more consistently in the back half of the year.
Got it. Thanks Christie. Thanks.
Our next question will come from Chris Pascal with nefron research. Your line is open,
Thanks. Uh, I wanted to ask a couple of questions on the robotics business. You know, the ortho robot landscape now includes a variety of different form factors. You've got some competitors taking more of a portfolio approach to try and provide different solutions to physicians who may have different preferences. You guys have been more "one size fits all" with Mo. Do you see a limit to that strategy, or do you think Mo in a single form factor can continue to kind of cover all your bases?
Yeah, listen, like I said before, I had a question earlier about a different product, we're not going to talk about our pipeline of, of robotic Solutions. And whether something will something else will be added to the Mako portfolio. I'm not going to preview that. So, that will happen if that's something like that happens. I'll let you know when it does, but we have a absolute winning solution right now. Winning the United States winning globally. We know we have the best robot on the market and our solution is at applications at applications continue. We're not finished, right? We we've got other applications planned that we're going to continue to add to the robot to create tremendous value. So household, buys 1, robot that gets all these different applications that they can use. So we we know that we're in a good position. We have a winning hand, we're going to continue to play this hand.
But could we do something different in the future? It's possible. We'll let you know at that time, but not before.
Okay. I think my follow-up question also straight into the pipeline territory, so maybe I'll, I'll pivot and ask about trauma. It's been a real standout. You noted that, you're now lapping the Pangaea launch. I know you guys tend to talk about product rollouts being multi-year Affairs. But how do you think about your ability to sustain double-digit trauma growth as those comps get tougher?
You know, we we sustain double digit growth in a lot of our businesses as comps, get tougher. You just look at neurocranial, just look at endoscopy. Look at this is something we do. I this this launch has been fantastic. Just an absolutely beautifully executed super complex launch. And we're we're we're actually still adding to it, so we just added some Mis plates. So it's such a comprehensive system that it's not like the launch ever completely stops. You're going to continue to add little features here and there to keep it fresh and it hasn't even launched yet in Europe. Um that won't be until next year that it starts. So this tremendous growth even owe us. Our growth is really strong in spite of pangi and not being everywhere in O us. So that combined with upper extremities being on fire, put an angle starting to get better. And certainly the, the change in reimbursement for total ankle where we, we have a very high market share is going to be exciting. Uh, time to beautifully with the launch of our incompass brand. New Total ankle. Uh just fortuitous for us.
Tells me that trauma experiences continue to be a high growth division for the company.
Great. Thank you.
Our next question.
With truist Securities. Your line is open.
Hi, thanks for taking the question. Uh, just 2 2, quick ones for me, following up to Chris's question, just in, on, on robotics portfolio. What's your view on? You know, fully autonomous robotic the competitor competitor obviously um, you know, has a solution or wants to solution there. You see the market going there, is there an appetite for that and then just a second question up, front here on neurovascular. Kevin, just curious if you can comment at all on on us, nervosa and Market, particularly in the scheme of growth,
Yeah, so let me start with the uh, with a with autonomous. Um, so just to be clear, you know, we're aware of their portfolio and
we know that they were pursuing autonomous. We have the capability today to do moons.
I've actually been in the lab where we I've actually seen it operate autonomously.
We have chosen not to pursue that because of the regulatory burden and the expenses required, to get it through FDA. And so at some point in the future, if if the market really has an appetite for autonomous, we can turn that that feature on.
and and but right now that's not our focus, our focus is using our R&D dollars to add new applications that provide tremendous value and even if they try to move our robot outside of the the haptic boundaries they can't
So, whether they're putting their hand on it, to make it move, or whether it's done autonomously. Honestly, that's not a big value. Add for surgeon in our, in our opinion, but should the market start to move? That way, we already have that capability today with makeup.
Continue to do well in the, in the hemorrhagic side of the market, uh, and the estimate Market was a little bit slower, and we've seen that market kind of vary from quarter to quarter and there's a lot of entrance in that market. Uh, obviously it was a bit of a soft quarter for us in neurovascular this quarter but we have 3 product launches that we mentioned in, um, in the prepared remarks that, that give us optimism, that we're going to have a much better second half.
Thank you.
Our next question will come from Mike Matson with medium and Company. Your line is open.
Yeah, thanks. I just want to follow up on the the nerve at the question. So you mentioned this Broadway, large for catheter? Uh, can you just tell us a little bit more about the timing on that and will that actually have labeling for for aspiration use for stroke?
Thank you. Yeah. So it it is approved and we we have just started to launch it with the sales force. So initial cases have gone extremely well, it's made completely different ways. So the manufacturing process is completely different to all of our existing um, catheter. So it's it's a proprietary manufacturing method that really improves trackability. It's, I think up the Luminous a 084, I believe Lumen size, so large Lumen, Lumen size, very trackable, getting great feedback. Uh, but it's just just being launched right now. So approved in the US being launched in the US, will take some time before it's launched and not in other markets around the world.
It is a cleared for delivery, use or for actual aspiration use.
It's cleared for aspirations.
Okay, all right. Thanks and then just 1 on shoulders. So I think shoulders have also started to move into the the ASC setting, so polish shoulder. So um, you know what, what are you seeing there? And you know, how does that kind of balance out to maybe increase volume but potential for some pricing pressure?
Yeah, we obviously have a a very expensive shoulder implant so really the best shoulder implants on the market with the perform um perform system. And there is a little bit less pricing in the ASC but more volume to pick up. And a lot of people suffer from the shoulders, we had another quarter, every quarter is, you know, good double digit growth in shoulder and we continue to to love our shoulder business. We also have some products and offerings that nobody else has.
Right? So we have the, the Hemi arthroplasty with pyrocarbon. You have the shoulder ID, which is a custom glenoid customized to the patient. So you don't have to have separate augments. And so, this pipeline is fantastic. The existing implants are modern. We have blueprint software to help with pre-planning, so we have just a terrific offering. And, and so, yes, we've lost a little bit of price on some of those procedures that I moved the AC, but it certainly hasn't slowed down our growth at all.
Let alone, the fact that next year we're going to move to full launch on Mako Mako shoulder. So I don't expect shoulder to be slowing down anytime soon.
Okay, thank you.
Our next question comes from shagun Singh. With RBC, your line is open.
So much uh, 2 quick ones for me. Uh, just on your implied, second half guide. It seems like a step down in the back, half versus a front half on an adjusted basis, you know, still really strong, but just wondering if it's conservatism or any factors to call out there. And then, for my second question, I was just wondering if Kevin, you could talk at high level or directionally on 2026 any areas that you are, um, you know, uh, most excited about. Um, and then, uh, you know, just thinking through 2026 as well. You know, we've been speaking with some hospitals, um, you know, especially those who have very high exposure to Medicare Medicaid. Uh, you know, they have talked about, uh, budgets coming down in 26 versus 25. Sounds like you're not hearing it, uh, about it in for, for 25, but just any color on 26, would be great. Thank you for taking the questions.
Hi. Can I take, I'll take the those questions. Uh first as as we think about the guy in the second half of the Year. Certainly we have higher higher comps as we think about our sales growth that we have to get through in the back half. But also as you know our our plan always is we want to we want to make sure that we beat and raise as we go throughout the year. And so I think we're very well set up to deliver on what
We have and and ideally if we over-performed to to raise guidance, as we as we continue to perform in the second half of the year as of as for 20126, you know, we're not going to provide any any update on 26 until we get through the end of this year. So uh, at this point, we have no no comments, uh, with regards to how how, you know, we think about 2026 at this point. Yeah. The the only thing I'd say shagun is that
Hospitals need our procedures. They are very Revenue producing.
Uh, the places that we play in healthcare and so if their financials are affected
Past, they're certainly not going to.
Come after. Our procedure areas that we're the ones that are making a lot of the money in the hospital. So if anything, they'd like to do more of our procedures to help with their financial pressure, so it'll take a long time before it really starts to hit our business based on where we play Within the Healthcare System.
Thank you.
And Chelsea with ubx, your line is open.
Hey, good afternoon, guys. Thanks so much for taking the question. Um, Kevin just 2 questions for me, first on China. Um, you know, I know you guys have highlighted this as an area where you're under indexed and it's a it's there's a lot of potential for growth there. I'm just curious, I mean there's been a lot of you know you know, it's been very evolving very quickly with Paris but also you know the broader Healthcare Market in China curious about how you're thinking about China from a growth perspective and how much that the focus for you guys today and then just 1 quick follow up after that.
Yeah, we don't have a large China business as you probably know and VPP hurt everybody for us a little bit less than some of our competitors, because of our presence. But look, it's a giant market long term, you have to be in China, you know, we're not withdrawing from China, but that we're also being very thoughtful about the types of Investments that we do, and having to have Sometimes some localized products, which we're experimenting with, uh, in our dossi division, as 1 example. Um, so we're being, I guess.
Careful and, and treading carefully is the way. I would describe it being thoughtful about our distributor arrangements. And, uh, it's not something that we're pouring a lot of money into, but, but we're not, uh, taking any steps to leave or to exit. Uh, we're going to hang in there and we're going to continue to
To sort of build have the building blocks to have a sustainable growing business and China, had a very good second, quarter of having a good year this year.
But we've been through some challenges in China, so I'm not nearly as bullish as I was, let's say 5 or 6 years ago before in the pre vbp era, um, it's, it's a lot different, the market right now, but it is a market that we're going to continue to be active in um, as we are in a lot of other International markets.
Okay. And then my
Is there anything structural about the international market that would make the ramp, um, look different, um, for Mo than it did in the, in the US, or should we think of the us as a good proxy for how to model Mo uptake? Um, over the next few years internationally. Thanks so much.
Yeah, thanks. It's it's a good proxy Japan. It's a good proxy for Japan. So Japan has a financial wherewithal. They like technology. They can afford this. So I say Japan's a good proxy and some of the European countries are good. Proxies the the countries that are not quite as good, a proxy would be something like France which is all government paid. It takes a long time and Canada is another example where all of a sudden
Sudden. They're now starting to be very interested in Niko because they've seen long-term data that shows that it's really high performing, the Australian data was tremendous. So it showed that Mo not only performed better than manual instruments, but performed better than navigation and that is very credible on a, on a global stage. So that data that came out is something that we're using internationally to help Drive the business. So, it does vary by country, I would say countries like the UK countries like Italy. They'll that will be moving kind of like the United States. But there's some other countries that are really socialized medicine, it will move a little bit slower. It's just the nature of the Beast.
Our next question will come from Matthew aspro with Jeff. Your line is open.
Thank you for taking the question. This is about Matt Taylor. I wanted to quickly ask about, or have you expand a little bit on how you're thinking about the recent obvious and the implications for your business?
Primarily.
Are you seeing any shifts in the behavior of purchasing or capex budgeting from hospitals, given the favorable capex treatments? They have from whatever accelerated depreciation and Etc and then also maybe a follow up to that is how should we be thinking about the tax rate for your business? Setting it to 2026
As procedures continue to be strong. Um, we expect that uh there'll be a high need of our capital and so we're positioned well on that front.
And as it relates to the tax implications uh of the bill. So so we, we expect that over the next year. So we will see some benefit in terms of our cash tax. Just given the bill. But from an ETR standpoint, we would we relatively be in the similar area that we are this year. So this year, our guide is 15 to 16% and as we get into next year, we'll we'll confirm what that's going to be, but we don't expect it to have a significant impact on our our ETR uh, at this point.
Great, thank you very much.
Our next question will come from Caitlyn Cronin with canaccord. Your line is open.
Great. Thanks so much for taking the questions and congrats on a great quarter. I guess, you know, just starting off with tips. I think it was a strong number. Are you guys seeing any pressure from? You know, the competitor launches in hips um, and then just any update on whether, uh, you're continuing to Trend higher and kind of the percent of skip procedures done, robotically,
Yes, I would say on robotic procedures trending, both knees and hips continued climb.
And we're very excited about the hip 4.0 software. Because if you recall the first 5 or 6 years, maybe 7 years after the acquisition, the hip percentage hadn't really changed very much. Uh but this new software is very good and especially now that we've added revision hip. I expect that to continue to improve. Insignia has been an absolute, um, home run of a product for us and has really taken off and I can't wait till for it to get approved in Europe. So that'll continue to contribute to our growth. We got a lot of training around direct anterior which has been terrific. And so overall, we we run a really good offense, uh, in terms of our commercial offense and we just focused more on ourselves and and what we're doing with the customers rather than focusing on the competition. And and that's been paying off for us.
That's great.
Was that related to you know, 2 guidelines the momentum in in the time frame you know, portion of the enabling tax portfolio.
Yes, that's exactly right. So when we say enabling Tech, we mean the cube guidance and the and the cube Guidance just as just a reminder with Michael 4, that's half of the system. And so you can use it for spine to do to do navigation, but you could also combine it with the make or robotic arm to use Mo. So, we use, we have this reuse of software type of approach, which is, uh, which is really effective. We also have the co-pilot product that's that's reported under our neurosurgery business under neurocranial
Which is a burr that has haptic feedback as you get close to the to the key critical um anatomy in the spine. That'll actually buzz and they actually turn off before the surgeon hits, those structures. So that has been very, very favorably received by customers. So to be able to use co-pilot, you have to have the queue guidance system. And so even though the revenue part of it is an enabling Tech and part of the revenue is in neurosurgery, it does operate as a system and we had a really good quarter with you too.
Great. Thank you.
Our next question comes from Josh Jennings with TV Cohen, your line is open.
Hi. This is Eric on for Josh, thank you for taking the question on Capital. Uh, I I understand you guys bucket items into large and capital items, um, for large items in particular, I was wondering if there's any detail you can share on the portion of outright Capital sales versus some financing options, or placements, for that category. And, um, maybe an easier 1 to answer is just whether or not that has seen any meaningful shifts in in the ratio over the past several quarters.
Yeah, this is Jason. I I'll take this 1. So as you think about our Capital as a, as a percent of kind of total revenue, right? You have about 15% of our total revenue. That's the smaller Capital more closely tied to procedures. Uh, and then you've got the larger Capital, uh, that's closer to 9 to 10 of our total revenue. Um, and and that business continues to do really well, I think Kevin mentioned earlier our Communications.
Business where you see uh, a large percentage of our large Capital. Uh, did really well in the quarter uh, and other areas of our business that has this large Capital as well continues to, to perform really well. So, um, we're we're really happy with both the large and small capital and the only Trend towards more financing has really been on the robots under Mo where there has been especially in the ASC. Most of those deals in the surgery centers are financed versus hospitals. Which tend
to do more outright for purchasing just historically, but not a major change that that we're seeing uh from the trend that we've seen over the over the past year to 18 months,
I know there's a question earlier on on Mako internationally but if I could focus on make a spine and shoulder in particular um appreciate the the reiteration of the US launch timeline there but was just curious if you could share your thinking around those new offerings and international markets and and what the commercial opportunity could look like outside the US,
Yeah, I would say the opportunity is large, right? And as you think about just the initial launch, we're we're we're looking at the end of this year for Maaco spine and then uh, the first part of next year for for Maaco shoulders. So it'll be a deliberate lengthy launch. Um but but yeah there's there's lots of opportunity both in the US and outside.
Okay.
Appreciate it. Thank you so much for the questions.
There are no further questions. I will turn the call over to Kevin Lobo for closing remarks.
Thank you all for joining our call. We look forward to sharing our Q3 results with you in October.
Thank you.